医疗保健提供者对医用大麻经验的认识和指导的影响。

Q1 Medicine
Medical Cannabis and Cannabinoids Pub Date : 2025-02-18 eCollection Date: 2025-01-01 DOI:10.1159/000544125
Thomas A Clobes, Marshall M Mee, Jenna M Jimenez, Jesus Maldonado, Joshua R Song
{"title":"医疗保健提供者对医用大麻经验的认识和指导的影响。","authors":"Thomas A Clobes, Marshall M Mee, Jenna M Jimenez, Jesus Maldonado, Joshua R Song","doi":"10.1159/000544125","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Cannabis as a therapeutic agent is accessible to a growing number of people, though research suggests that many medical cannabis (MC) users undertake their cannabinoid therapy independently, without collaborating with a cannabis clinician or informing their primary care provider (PCP). The effects of medical collaboration or disclosure to PCP on outcomes of cannabinoid therapy are unknown. Researchers anticipate that those who collaborate with a cannabis clinician or disclose their medical cannabis use to their PCP will find MC to be more effective, use less delta-9-tetrahydrocannabinol (THC) and more cannabidiol (CBD), and experience fewer side effects.</p><p><strong>Methods: </strong>Through an online survey, medical cannabis users reported their cannabis usage patterns, health outcomes, PCP awareness, and collaboration with cannabis clinicians. These responses were analyzed using a variety of statistical tests to search for differences in reported efficacy, specific cannabinoid, and side effects between different levels of medical professional involvement (<i>n</i> = 988).</p><p><strong>Results: </strong>Patients who either worked with a cannabis clinician or reported their use of their PCP reported significantly higher efficacy (<i>p</i> < 0.001), and in the case of working specifically with a cannabis clinician, higher daily doses of cannabidiol were used (<i>p</i> < 0.001). CBD doses did not vary between those who had disclosed their MC use to their PCP and those who had not. There were no significant differences in THC doses or side effects identified between groups.</p><p><strong>Conclusion: </strong>The results indicated that undertaking cannabinoid therapy with PCP awareness or guidance from a cannabis clinician is associated with better outcomes.</p>","PeriodicalId":18415,"journal":{"name":"Medical Cannabis and Cannabinoids","volume":"8 1","pages":"47-57"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11919312/pdf/","citationCount":"0","resultStr":"{\"title\":\"Impact of Healthcare Provider Awareness and Guidance on the Medical Cannabis Experience.\",\"authors\":\"Thomas A Clobes, Marshall M Mee, Jenna M Jimenez, Jesus Maldonado, Joshua R Song\",\"doi\":\"10.1159/000544125\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Cannabis as a therapeutic agent is accessible to a growing number of people, though research suggests that many medical cannabis (MC) users undertake their cannabinoid therapy independently, without collaborating with a cannabis clinician or informing their primary care provider (PCP). The effects of medical collaboration or disclosure to PCP on outcomes of cannabinoid therapy are unknown. Researchers anticipate that those who collaborate with a cannabis clinician or disclose their medical cannabis use to their PCP will find MC to be more effective, use less delta-9-tetrahydrocannabinol (THC) and more cannabidiol (CBD), and experience fewer side effects.</p><p><strong>Methods: </strong>Through an online survey, medical cannabis users reported their cannabis usage patterns, health outcomes, PCP awareness, and collaboration with cannabis clinicians. These responses were analyzed using a variety of statistical tests to search for differences in reported efficacy, specific cannabinoid, and side effects between different levels of medical professional involvement (<i>n</i> = 988).</p><p><strong>Results: </strong>Patients who either worked with a cannabis clinician or reported their use of their PCP reported significantly higher efficacy (<i>p</i> < 0.001), and in the case of working specifically with a cannabis clinician, higher daily doses of cannabidiol were used (<i>p</i> < 0.001). CBD doses did not vary between those who had disclosed their MC use to their PCP and those who had not. There were no significant differences in THC doses or side effects identified between groups.</p><p><strong>Conclusion: </strong>The results indicated that undertaking cannabinoid therapy with PCP awareness or guidance from a cannabis clinician is associated with better outcomes.</p>\",\"PeriodicalId\":18415,\"journal\":{\"name\":\"Medical Cannabis and Cannabinoids\",\"volume\":\"8 1\",\"pages\":\"47-57\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-02-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11919312/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Cannabis and Cannabinoids\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000544125\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Cannabis and Cannabinoids","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000544125","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

导言:越来越多的人可以获得大麻作为一种治疗剂,但研究表明,许多医用大麻使用者在不与大麻临床医生合作或不通知其初级保健提供者的情况下独立进行大麻素治疗。医疗合作或向PCP披露对大麻素治疗结果的影响尚不清楚。研究人员预计,那些与大麻临床医生合作或向PCP透露其医用大麻使用情况的人会发现MC更有效,使用更少的德尔塔-9-四氢大麻酚(THC)和更多的大麻二酚(CBD),并且副作用更少。方法:通过在线调查,医用大麻使用者报告了他们的大麻使用模式、健康结果、PCP意识以及与大麻临床医生的合作。使用各种统计检验对这些反应进行分析,以寻找不同医疗专业参与水平之间报告的疗效、特定大麻素和副作用的差异(n = 988)。结果:与大麻临床医生一起工作或报告使用PCP的患者报告了显着更高的疗效(p < 0.001),并且在专门与大麻临床医生一起工作的情况下,使用了更高的大麻二酚日剂量(p < 0.001)。CBD的剂量在那些向PCP透露使用MC的人和没有透露的人之间没有变化。四氢大麻酚的剂量和副作用在两组之间没有显著差异。结论:结果表明,在大麻临床医生的指导下,在PCP意识下进行大麻素治疗可获得更好的结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Impact of Healthcare Provider Awareness and Guidance on the Medical Cannabis Experience.

Introduction: Cannabis as a therapeutic agent is accessible to a growing number of people, though research suggests that many medical cannabis (MC) users undertake their cannabinoid therapy independently, without collaborating with a cannabis clinician or informing their primary care provider (PCP). The effects of medical collaboration or disclosure to PCP on outcomes of cannabinoid therapy are unknown. Researchers anticipate that those who collaborate with a cannabis clinician or disclose their medical cannabis use to their PCP will find MC to be more effective, use less delta-9-tetrahydrocannabinol (THC) and more cannabidiol (CBD), and experience fewer side effects.

Methods: Through an online survey, medical cannabis users reported their cannabis usage patterns, health outcomes, PCP awareness, and collaboration with cannabis clinicians. These responses were analyzed using a variety of statistical tests to search for differences in reported efficacy, specific cannabinoid, and side effects between different levels of medical professional involvement (n = 988).

Results: Patients who either worked with a cannabis clinician or reported their use of their PCP reported significantly higher efficacy (p < 0.001), and in the case of working specifically with a cannabis clinician, higher daily doses of cannabidiol were used (p < 0.001). CBD doses did not vary between those who had disclosed their MC use to their PCP and those who had not. There were no significant differences in THC doses or side effects identified between groups.

Conclusion: The results indicated that undertaking cannabinoid therapy with PCP awareness or guidance from a cannabis clinician is associated with better outcomes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Medical Cannabis and Cannabinoids
Medical Cannabis and Cannabinoids Medicine-Complementary and Alternative Medicine
CiteScore
6.00
自引率
0.00%
发文量
18
审稿时长
18 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信